Abstract: A test device for detecting the presence of a residue analyte in a sample includes a support strip and a sample-absorbing matrix attached to the support strip. The sample-absorbing matrix has a material for absorbing an amount of the sample. The test device also includes a mobile-phase support for holding a mobile-phase composition. The mobile-phase support is attached to the support strip and in contact with the sample-absorbing matrix. A mobile-phase composition is disposed on the mobile-phase support and has a receptor for binding with the analyte. The mobile-phase composition can be carried in the sample. A stationary-phase membrane is attached to the support strip and has a first membrane end in contact with the mobile-phase composition and a second membrane end. The membrane allows lateral capillary flow of the sample from the first membrane end to the second membrane end.

Abstract: An anti-KC-4 humanized monoclonal antibody that comprises the variable regions of the light and heavy chains of the anti-KC-4 murine antibody, wherein the light chain has 7 amino acids and the heavy chain has 12 amino acids of the framework regions substituted with amino acid present in equivalent positions in antibodies of a species other than munne, and the constant regions of a human antibody. The antibody may be labeled and/or glycosylated, and is presented as a composition with a carrier. The anti-KC-4 monoclonal antibody is used in diagnostic kits for cancer and in in vivo methods of imaging and treating a primary or metastasized cancer, and in vitro diagnosis and ex vivo purging neoplastic cells from a biological fluid. RNAs and DNAs encode the monoclonal antibody, and a hybrid vector carrying the nucleotides and transfected cells express the peptides.

Abstract: A variant of a polypeptide comprising a human IgG Fc region is described, which variant comprises an amino acid substitution at amino acid position 329, or at two or all of amino acid positions 329, 331 and 322 of the human IgG Fc region. Such variants display altered effector function. For example, C1q binding and/or complement dependent cytotoxicity (CDC) activity may be reduced or abolished in the variant polypeptide. The application also describes an immune complex and an assay for determining binding of an analyte, such as an Fc region-containing polypeptide, to a receptor.

Abstract: An analytical system for rapid detection and identification of different analytes directly from a test sample by mixing test material with a germinogenic source and enzyme-free spores, allowing the mixture to stand for a time to allow analyte-induced spore germination and subsequent de novo synthesis of an enzyme capable of producing a germinant in the presence of the germinogenic source and detecting the presence of a germination-derived product. The germinant which is formed promotes further spore germination with concomitant additional de novo enzyme synthesis which results in a propagating cascade of analyte-independent germination after which a germination-derived product can be easily detected. The technique is particularly efficient to conduct thousands of parallel assays in an array of microscopic wells.

Abstract: The present invention relates to the use of heparan sulfate, or a biological equivalent thereof, to regulate nucleic acid expression, expression of cell receptors, and infection by hepatitis B virus.

Abstract: This invention provides means and methods of inactivating viruses and other organisms in cell-containing or biopolymer-containing compositions without significant alteration of proteins or other biopolymers by contacting such compositions with selective ethyleneimine oligomer inactivating agents, such as the trimer or tetramer.

Abstract: A method for prophylactic or therapeutic treatment of a disease or bodily condition that is caused or affected by a hormonal or metabolic disorder, such as cystic ovarian disease, temporary infertility, permanent infertility, lack of menstrual cycles, irregular menstrual cycles, and nymphomania, includes administering to a mammal a lysozyme dimer in an amount effective for preventing or treating said disease or condition.

Abstract: The means and methods of inactivating viruses and other organisms in cell-containing or biopolymer-containing compositions comprising contacting such compositions with selective ethyleneimine oligomer inactivating agents are disclosed. The means and methods of this invention selectively modify functional nucleic acids in a cell-containing or biopolymer-containing composition using selective ethyleneimine oligomer inactivating agents, such as the trimer or tetramer without significant alteration of proteins or other biopolymers.

Abstract: Method and assay kit for positively identifying HTLV-I and HTLV-II infection from human serum samples. The kit includes peptide antigens from the C-terminal regions of HLTV-I p19 and HTLV-II p21 gag proteins, and peptide antigens from the HLTV-I and HTLV-II env proteins immobilized on a solid support. After reaction of the serum sample with the solid support, an antibody-detection reagent in the kit is added to the support, to detect binding of human serum antibodies to each of the peptide antigens separately. The test allows positive identification of HTLV-I or HTLV-II when antibody binding to each HTLV-I or HTLV-II gag and env peptide antigen, respectively, is observed. Also disclosed is a kit for screening human sera for evidence of HTLV-I or HTLV-II infection.

Abstract: The present invention is drawn to a method for the rapid assessment of organ status, including organ damage following immunological or toxicological insult, in a subject based on the detection of one or more isoenzymes of glutathione S-transferase (GST) in diverse biological fluids comprising contacting a particle-labelled anti-GST antibody specific for said isoenzyme with a sample of a biological fluid suspected of containing said isoenzyme, said antibody having a sensitivity sufficient to detect at least a picomolar amount of said isoenzyme, and capturing the particle-labelled antibody-isoenzyme complex on an immobolised capture antibody to generate a visually detectable signal.

Abstract: A make-up composition in the form of a water-in-oil or oil-in-water emulsion comprising silicone oil selected from volatile silicones, non-volatile silicones and mixtures thereof, optionally humectant, at least one coated or uncoated iron-oxide type pigment and a TiO.sub.2 -coated platelet-type interference pigment material having a TiO.sub.2 layer thickness of from about 120 nm to about 160 nm or a whole number multiple thereof.

Abstract: A method for producing an improved solid phase antigenic reagent useful in an immunoassay for detecting antibodies specific for a virus, such as the human immunodeficiency virus, is disclosed which comprising the addition to a natural viral lysate a synthetic or recombinant viral protein or peptide. Also provided is an improved immunoassay utilizing the solid phase antigenic reagent.